ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium

0396181 - ÚEM 2014 RIV GR eng J - Článek v odborném periodiku
Rizzato, C. - Campa, D. - Pezzilli, R. - Souček, P. - Greenhalf, W. - Capurso, G. - Talar-Wojnarowska, R. - Heller, A. - Jamroziak, K. - Khaw, K. T. - Key, T. - Bambi, F. - Landi, S. - Mohelníková-Duchoňová, B. - Vodičková, Ludmila - Buechler, M. W. - Bugert, P. - Vodička, Pavel - Neoptolemos, J. P. - Werner, J. - Hoheisel, J. D. - Bauer, A. S. - Giese, N. - Canzian, F.
ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium.
Oncology Reports. Roč. 29, č. 4 (2013), s. 1637-1644. ISSN 1021-335X. E-ISSN 1791-2431
Institucionální podpora: RVO:68378041
Klíčová slova: pancreatic cancer * genetic susceptibility * cancer risk
Kód oboru RIV: EB - Genetika a molekulární biologie
Impakt faktor: 2.191, rok: 2013

There is strong epidemiologic evidence indicating that common genetic variability could be implicated in pancre¬atic cancer risk and, to date, various loci have been proposed. In particular, there is increasing evidence of the involvement of ABO gene variability and pancreatic cancer risk. In a large multicentric study of 1,028 pancreatic ductal adenocarcinoma cases and 2,257 controls in the context of the PANcreatic Disease ReseArch (PANDoRA) consortium, we investigated the suggested association with increased risk for carriers of single nucleotide polymorphisms (SNPs) determining the A or B allele in comparison with the O allele, which encodes for a non-functional enzyme. In our analysis, carriers of the A1 were indeed at greater risk of developing the disease. In addition, we investigated the possible influence that genetic variability at the ABO locus may have in pancreatic cancer survival, but we observed no effect in our population.
Trvalý link: http://hdl.handle.net/11104/0223998